CRBP (Corbus Pharmaceuticals Holdings, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CRBP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Yong Ben | Director | Sell | — | — |
| 2026-08-17 | Leonardo Viana Nicacio | Chief Medical Officer | A | — | — |
| 2026-08-12 | Nishant C Saxena | Chief Business Officer | Buy | — | — |
| 2026-08-10 | Sean F. Moran | Chief Financial Officer | Sell | — | — |
| 2026-08-10 | Yuval Cohen | Chief Executive Officer | Sell | — | — |
| 2026-06-11 | Anne Altmeyer | Director | Sell | — | — |
| 2026-06-11 | Winston Kung | Director | Sell | — | — |
| 2026-06-11 | John Kenneth Jenkins | Director | Sell | — | — |
| 2026-06-03 | Nishant C Saxena | Chief Business Officer | Buy | — | — |
| 2026-05-22 | Nishant C Saxena | Chief Business Officer | A | — | — |
| 2026-05-21 | John Kenneth Jenkins | Director | A | — | — |
| 2026-05-21 | Rachelle Suzanne Jacques | Director | A | — | — |
| 2026-05-21 | Brent Pfeiffenberger | Director | A | — | — |
| 2026-05-21 | Yong Ben | Director | A | — | — |
| 2026-05-21 | Anne Altmeyer | Director | A | — | — |
| 2026-05-21 | Winston Kung | Director | A | — | — |
| 2026-03-04 | Dominic Smethurst | Chief Medical Officer | Sell | — | — |
| 2026-02-18 | Sean F. Moran | Chief Financial Officer | Sell | — | — |
| 2026-02-18 | Yuval Cohen | Chief Executive Officer | Sell | — | — |
| 2026-02-18 | Ian Hodgson | Chief Operating Officer | Sell | — | — |
| 2026-02-04 | Ian Hodgson | Chief Operating Officer | Sell | — | — |
| 2026-02-04 | Dominic Smethurst | Chief Medical Officer | Sell | — | — |
| 2026-01-16 | Yuval Cohen | Chief Executive Officer | A | — | — |
| 2026-01-16 | Ian Hodgson | Chief Operating Officer | A | — | — |
| 2026-01-16 | Sean F. Moran | Chief Financial Officer | A | — | — |
| 2026-01-16 | Dominic Smethurst | Chief Medical Officer | A | — | — |
| 2025-12-15 | Cormorant Asset Management, LP | 10%+ Owner | Sell | — | — |
| 2025-10-27 | Sean F. Moran | Chief Financial Officer | MIXED | — | — |
| 2025-10-27 | Yuval Cohen | Chief Executive Officer | MIXED | — | — |
| 2025-10-21 | Anne Altmeyer | Director | MIXED | — | — |
| 2025-06-02 | ALAN F HOLMER | Director | A | — | — |
| 2025-06-02 | Winston Kung | Director | A | — | — |
| 2025-06-02 | Rachelle Suzanne Jacques | Director | A | — | — |
| 2025-06-02 | Anne Altmeyer | Director | MIXED | — | — |
| 2025-06-02 | John Kenneth Jenkins | Director | MIXED | — | — |
| 2025-06-02 | Yong Ben | Director | A | — | — |
| 2025-03-07 | Dominic Smethurst | Chief Medical Officer | Sell | — | — |
| 2025-02-18 | Sean F. Moran | Chief Financial Officer | Sell | — | — |
| 2025-02-18 | Yuval Cohen | Chief Executive Officer | Sell | — | — |
| 2025-02-04 | Yuval Cohen | Chief Executive Officer | A | — | — |
| 2025-02-04 | Dominic Smethurst | Chief Medical Officer | A | — | — |
| 2025-02-04 | Sean F. Moran | Chief Financial Officer | A | — | — |
| 2024-09-24 | Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | Buy | — | — |
| 2024-08-20 | Winston Kung | Director | A | — | — |
| 2024-06-18 | Sean F. Moran | Chief Financial Officer | MIXED | — | — |
| 2024-06-18 | Yuval Cohen | Chief Executive Officer | MIXED | — | — |
| 2024-06-14 | ALAN F HOLMER | Director | M | — | — |
| 2024-06-03 | AVERY W CATLIN | Director | A | — | — |
| 2024-06-03 | Anne Altmeyer | Director | A | — | — |
| 2024-06-03 | Yong Ben | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,349,231 | — |
| — | 10%+ Owner | 2,344,971 | — |
| — | 10%+ Owner | 1,475,000 | — |
| — | Chief Executive Officer | 157,316 | — |
| — | 10%+ Owner | 119,819 | — |
| — | Chief Medical Officer | 89,790 | — |
| — | Chief Financial Officer | 84,694 | — |
| — | Chief Business Officer | 77,900 | — |
| — | President and CSO | 70,347 | — |
| — | Chief Medical Officer | 58,333 | — |
| — | Chief Operating Officer | 51,080 | — |
| — | Director | 22,817 | — |
| — | Director | 12,140 | — |
| — | Director | 11,383 | — |
| — | Director | 10,629 | — |
| — | Director | 9,383 | — |
| — | Director | 7,579 | — |
| — | Director | 7,500 | — |
| — | Chief Medical Officer | 6,874 | — |
| — | Director | 4,350 | — |
| — | Director | 3,833 | — |
| — | Director | 2,783 | — |
| — | Chief Operating Officer | 1,183 | — |
| — | Chief Operating Officer | 900 | — |
| — | Director | 476 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRBP quote page; the site-wide leaderboard is on the insider transactions hub.